Emergence of continuous glucose monitoring systems is a major breakthrough in the glucose monitoring for diabetic patients. Medtronic and Dexcom are the only major players in this industry followed by Abbott in few regions. Companies are focusing more on research and development before introducing their products in the market. CGMS are highly regulated and go through strict tests before being approved. CGM manufacturers have faced competition from self-monitoring blood glucose devices (SMBG). SMBG devices are cheaper and easy to use and have an less stringent approval process from authorities like FDA. SMBG has more number of players and larger market share. However, CGM systems have been able to make a good market entry in the U.S. and are following the trend in other territories. CGM system market has seen good growth rates in past three years. Medtronic and Dexcom have introduced new systems which have witnessed lower frequency of errors. The MARD value for new sensors has decreased, new devices need lesser calibrations per day and most of the devices are approved for paediatric use. This has led to 50-60 percent jump in the revenues of some manufacturers.
Companies profiled include
1. Medtronic Inc.
2. Dexcom
3. Abbott
4. Johnson And Johnson (Animas Corp)
5. Insulet Corp
6. Tandem Diabetes
7. Echo Therapeutics

This Occams Research Report covers
1. Historical data
2. Revenue forecasts, growth rates and CAGR upto 2022
3. Industry Analysis
4. Competitive Analysis
5. Key geographic growth data
6. Deep profiles top competitive companies